Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses

Name: Correlation of 1846G&gt;A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses
SKU: 25309
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 52 No. 3 Articles 2022 Tags: AA Parkhomenko, alcoholic hallucinosis, cyp2d6, DA Sychev, EA Bryun, haloperidol, IA Zaytsev, KA Akmalova, MS Zastrozhin, NP Denisenko, personalized medicine, pharmacogenetics, SA Pozdniakov, VA Ivanchenko, VV Noskov, VYu Skryabin

Description

Description

Drug Disposition & Pharmacokinetics

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses

By AA Parkhomenko, MS Zastrozhin, VYu Skryabin, VA Ivanchenko, SA Pozdniakov, VV Noskov, IA Zaytsev, NP Denisenko, KA Akmalova, EA Bryun, DA Sychev

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses

Description

Drug Disposition & Pharmacokinetics

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Zonisamide for Bipolar Depression by Deborah Dauphinais

Title

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses

Description

Drug Disposition & Pharmacokinetics

Related products

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Zonisamide for Bipolar Depression by Deborah Dauphinais

Title